Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VENT 03

Next Previous
X
Search
Drug Profile

VENT 03

Alternative Names: Cyclic GMP-AMP synthase (cGAS) inhibitor program - Ventus Therapeutics; VENT-03

Latest Information Update: 04 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventus Therapeutics
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action CGAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus
  • Preclinical Immunological disorders; Inflammation; Skin disorders

Most Recent Events

  • 31 Oct 2024 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Systemic lupus erythematosus (In volunteers) released by Ventus Therapeutics
  • 31 Oct 2024 Ventus Therapeutics completes a phase I trial in Systemic lupus erythematosus (In volunteers) in Netherlands (PO) (EUCT2023-507504-31-00)
  • 31 Oct 2024 Ventus Therapeutics plans a phase II trial for Systemic lupus erythematosus (PO) in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top